Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chesterman

Showing results (311-320 of 340) with videos related to

Pageof 34
Sort By:
Clinical and Experimental Immunology|September 1, 1989
Occurrence of platelet-activating factor (PAF) and an endogenous inhibitor of platelet aggregation in diffuse cutaneous mastocytosisJ L Macpherson, A Kemp, M Rogers, et al.
Blood|July 15, 1991
Establishment in culture and characterization of a strain with mast cell and monocytic properties from the bone marrow of a child with diffuse cutaneous mastocytosisS A Krilis, S G Warneford, J Macpherson, et al.
The American Journal of Pathology|August 25, 2007
Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategiesRavinay Bhindi, Roger G Fahmy, Harry C Lowe, et al.
AAPS Open|August 29, 2025
Bardoxolone methyl improves survival and reduces clinical measures of kidney injury in tumor-bearing mice treated with cisplatinLauren E Thompson, Stacey M Tuey, Paola Garcia Gonzalez, et al.
Parkinson'S Disease|September 2, 2025
Feasibility and Acceptability of Intervention and Trial Procedures of the UCL Live Well With Parkinson's Self-Management ToolkitTasmin Rookes, Megan Armstrong, Kate Walters, et al.
The New England Journal of Medicine|March 14, 1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study GroupM M Koopman, P Prandoni, F Piovella, et al.
Thrombosis and Haemostasis|January 31, 2002
Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome studyB H Chong, A S Gallus, J F Cade, et al.
FASEB Bioadvances|August 8, 2024
Bactericidal human monoclonal antibody 1B1 shows specificity for meningococcal factor H binding protein variant 2 and displaces human factor HDaniele Veggi, Chelsy C Chesterman, Laura Santini, et al.
Cancer Treatment Reports|December 1, 1987
Oral idarubicin as single-agent treatment of acute nonlymphocytic leukemia in poor-risk patientsR M Lowenthal, C N Chesterman, J D Griffiths, et al.
BMJ Open|June 10, 2022
Acceptance commitment therapy (ACT) for psychological distress associated with inflammatory bowel disease (IBD): protocol for a feasibility trial of the ACTforIBD programmeSubhadra Evans, Lisa Olive, Madeleine Dober, et al.
Pageof 34

Showing results (311-320 of 340) with videos related to

Sort By:
Pageof 34
Clinical and Experimental Immunology|September 1, 1989
Occurrence of platelet-activating factor (PAF) and an endogenous inhibitor of platelet aggregation in diffuse cutaneous mastocytosisJ L Macpherson, A Kemp, M Rogers, et al.
Blood|July 15, 1991
Establishment in culture and characterization of a strain with mast cell and monocytic properties from the bone marrow of a child with diffuse cutaneous mastocytosisS A Krilis, S G Warneford, J Macpherson, et al.
The American Journal of Pathology|August 25, 2007
Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategiesRavinay Bhindi, Roger G Fahmy, Harry C Lowe, et al.
AAPS Open|August 29, 2025
Bardoxolone methyl improves survival and reduces clinical measures of kidney injury in tumor-bearing mice treated with cisplatinLauren E Thompson, Stacey M Tuey, Paola Garcia Gonzalez, et al.
Parkinson'S Disease|September 2, 2025
Feasibility and Acceptability of Intervention and Trial Procedures of the UCL Live Well With Parkinson's Self-Management ToolkitTasmin Rookes, Megan Armstrong, Kate Walters, et al.
The New England Journal of Medicine|March 14, 1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study GroupM M Koopman, P Prandoni, F Piovella, et al.
Thrombosis and Haemostasis|January 31, 2002
Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome studyB H Chong, A S Gallus, J F Cade, et al.
FASEB Bioadvances|August 8, 2024
Bactericidal human monoclonal antibody 1B1 shows specificity for meningococcal factor H binding protein variant 2 and displaces human factor HDaniele Veggi, Chelsy C Chesterman, Laura Santini, et al.
Cancer Treatment Reports|December 1, 1987
Oral idarubicin as single-agent treatment of acute nonlymphocytic leukemia in poor-risk patientsR M Lowenthal, C N Chesterman, J D Griffiths, et al.
BMJ Open|June 10, 2022
Acceptance commitment therapy (ACT) for psychological distress associated with inflammatory bowel disease (IBD): protocol for a feasibility trial of the ACTforIBD programmeSubhadra Evans, Lisa Olive, Madeleine Dober, et al.
Pageof 34